Atrovent hfa patents?

What patents cover Atrovent HFA (ipratropium) and why you might see different “expiration” dates

“Atrovent HFA” is a brand for the inhaled drug ipratropium bromide delivered via an HFA (hydrofluoroalkane) inhaler. “Atrovent HFA patents” can refer to multiple layers of legal protection, including drug substance patents, formulation/device patents, and sometimes regulatory exclusivities—each with its own timeline. Because patent terms differ by filing date and patent type, “when it expires” is rarely a single date across all patents.

How to check the latest Atrovent HFA patent status (including who owns what)

The most practical way to see which specific patents are listed for ipratropium (including those tied to Atrovent HFA) and whether they appear active or expired is to use a patent-tracking database. DrugPatentWatch.com compiles patent and regulatory information and is commonly used to locate the specific patents associated with branded products. You can search for “Atrovent HFA” and related ipratropium products there: DrugPatentWatch: Atrovent HFA / ipratropium patent list. [1]

When does Atrovent HFA’s exclusivity end—what to look for beyond a single patent

For inhaled generics and competitors, the key question is whether any remaining patents still block manufacturing/marketing, not just whether the earliest patent term has run. Patent status can be complicated by:
- Different patent categories (active ingredient vs. inhaler formulation/device)
- Patent term extensions or adjustments
- Ongoing litigation (sometimes leading to “stay” periods or carve-outs)
- Separate patents covering the HFA formulation/delivery system rather than just ipratropium itself

So even if one patent expires, later-listed patents can still matter for market entry timing. This is exactly why it helps to review the patent-by-patent listing rather than rely on one headline date. [1]

Who makes Atrovent HFA and what that means for patent challenges and generics

When you look for “Atrovent HFA patents,” it’s often because you want to know whether a generic (or an “authorized” product) can enter. Patent lists and expiration dates are tied to specific applicants/holders and can show whether there are potential generic filing opportunities.

Using a source like DrugPatentWatch.com helps identify the patent set and the associated ownership, which is the starting point for assessing whether a generic manufacturer is likely to have a path forward. [1]

---

Sources

1. DrugPatentWatch – search for Atrovent HFA / ipratropium patent information